NCT03050463View on ClinicalTrials.gov

Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer

CompletedOBSERVATIONAL
Enrollment

178

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

March 6, 2021

Study Completion Date

July 8, 2021

Conditions
Healthy SubjectStage 0 Breast CancerStage IA Breast CancerStage IB Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood and saliva sample collection

PROCEDURE

Functional Magnetic Resonance Imaging

Undergo fMRI related tasks

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Stanford University

OTHER

NCT03050463 - Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer | Biotech Hunter | Biotech Hunter